An interventional study of SuperCAP intervention program and Psychoeducational intervention in Post COVID Condition, sponsored by Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Post-Acute COVID-19 Syndrome · Spain.
Among the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, this one is the 8th largest by planned enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2026, is one of 31 with no phase, reaches primary completion later than 10 of the 15 other live ones, and was the 47th registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →13 of the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain are open now. Recruiting first, the newest first:
Instituto de Investigación Biomédica de Salamanca · Sites in Spain
Ages 18+
Instituto de Investigación Sanitaria Aragón · Sites in Spain
Ages 18+
Universidad Rey Juan Carlos · Sites in Spain
Ages 18+
Hellenic Institute for the Study of Sepsis · Sites in Spain, Germany, Greece and 1 more country
Ages 18+
Universidad Rey Juan Carlos · Sites in Spain
Ages 18–60 · Women only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 1
First in 2021; this study’s year is marked. 5 started in 2026.
This study's planned enrollment of 100 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 60 across the 39 interventional studies, 184 across the 13 observational. Of the 30 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 52 have an industry lead sponsor. The 10 most frequent:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia is the lead sponsor of 45 studies on the registry; 3 are open to participants now.
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia has 4 studies filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Post-Acute COVID-19 Syndrome with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07530757Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaSuperCAP Program to Improve Cognition and Daily Functioning in Post-COVID-19 Condition | 2026-11 |
| NCT06928480Instituto de Investigación Sanitaria AragónEffectiveness and Acceptability of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in People With Long COVID-19. | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to determine whether the SuperCAP intervention program is superior to control in reducing disability from baseline to the post-intervention assessment in people with Post-COVID-19 Condition.
The main question it aims to answer is whether participants assigned to SuperCAP experience a greater reduction in disability, defined as an improvement of at least 5 points on the WHODAS 2.0 from baseline to the post-intervention visit, compared with participants in the control group.
Participants assigned to the SuperCAP intervention will undergo a series of sessions that include psychoeducation, adaptive cognitive training exercises, fatigue self-management strategies, and multidisciplinary content.
-COVID-19 Condition (PCC) is a major public health challenge, with cognitive impairment and fatigue among its most prevalent and disabling symptoms, leading to substantial limitations in quality of life and daily functioning. Digital health solutions provide an opportunity to expand access to structured, evidence-informed care. SuperCAP was developed as a multidisciplinary digital therapeutic program to support cognitive and functional recovery in individuals with PCC. A randomized pilot study demonstrated its feasibility and acceptability, supporting the conduct of a larger randomized controlled trial to evaluate its efficacy on disability and cognitive outcomes.
Participants will be randomized (1:1) to receive the digital intervention (SuperCAP) or Standard of Care (SoC) during 13 weeks, followed by a 12-week observation period.
The primary objective is to determine whether the SuperCAP intervention program is superior to control in reducing disability from baseline to the post-intervention assessment.
The secondary objectives include evaluating the effects of SuperCAP on quality of life, daily functioning, cognitive and emotional outcomes, the durability of these effects at follow-up, and the feasibility and acceptability of program implementation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The intervention comprises 60 sessions delivered over 12 weeks (5 sessions/week), with flexibility up to 15 weeks to accommodate symptom fluctuation. Each session follows a standardized structure to reinforce self-management and cognitive engagement. The sessions includes psychoeducation, adaptive cognitive training exercises, fatigue self-management strategies, and multidisciplinary content.
Device: SuperCAP intervention program
The Standard of Care consists in a psychoeducational intervention on the cognitive disorders and fatigue associated with long COVID, and general guidelines on how to manage these symptoms so that they have the least possible impact on daily life.
Other: Psychoeducational intervention
The SuperCAP (Supervised Computerized Active Program) is an online, multidimensional therapeutic program integrated into eSalut, the Catalan Institute of Health's digital platform, designed to improve daily functioning and quality of life in individuals with PCC who experience cognitive symptoms
The psychoeducational intervention is a non-pharmacological interventions that teach practical strategies to help individuals with the cognitive disorders and fatigue associated with long COVID and provide general guidelines on how to manage these symptoms so that they have the least possible impact on daily life.
To determine whether the SuperCAP intervention program is superior to control in reducing disability.
Change in total WHODAS 2.0 score from baseline to post-intervention.
Time frame: From baseline (week 0) to the post-intervention assessment (week 13).
To assess whether the SuperCAP intervention leads to greater improvements in quality of life compared with control.
Change in EuroQol 5 Dimensions (EQ-5D) score from -0,654 to 1 where higher scores mean better outcome.
Time frame: From baseline (week 0) to post-intervention (week 13)
To assess whether the SuperCAP intervention leads to greater improvements in instrumental daily functioning compared with control.
Change in Instrumental Activities of Daily Living (IADL) score from 0 to 8 where higher score mean better outcomes.
Time frame: From baseline (week 0) to post-intervention (week 13).
To evaluate whether the intervention improves performance-based cognitive measures.
Change in Montreal Cognitive Assessment (MoCA) total score from 0 to 30 where higher scores mean better outcomes.
Time frame: From baseline (week 0) to post-intervention (week 13).
To evaluate whether the intervention improves patient-reported cognitive functioning.
Change in subjective cognitive functioning in daily life by Memory Failures of Everyday Questionnaire (MFE-30) with scores from 0 to 120 where higher scores mean worse outcomes.
Time frame: From baseline (week 0) to post-intervention (week 13).
To assess reductions in depressive symptoms following the intervention.
Change in Patient Health Questionnaire-9 (PHQ-9) with scores from 0 to 27 where higher scores means worse outcomes.
Time frame: From baseline (week 0) to post-intervention (week 13)
To assess reductions in anxiety symptoms following the intervention.
Change in Generalized Anxiety Disorder-7 (GAD-7) score from 0 to 21 where higher scores mean worse outcomes.
Time frame: From baseline (week 0) to post-intervention (week 13).
To determine whether improvements in functional outcomes are sustained at follow-up.
Change in World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) score from 0 to 144 where higher scores mean worse outcomes.
Time frame: From post-intervention (week 13) to follow-up (week 25).
To determine whether improvements in cognitive outcomes are sustained at follow-up.
Change in Montreal Cognitive Assessment (MoCA) score from 0 to 30 where higher scores mean better outcomes.
Time frame: From post-intervention (week 13) to follow-up (week 25).
To determine whether improvements in emotional outcomes are sustained at follow-up.
Change in EuroQol 5 Dimensions (EQ-5D) score from -0,654 to 1 where higher scores mean better outcomes.
Time frame: From post-intervention (week 13) to follow-up (week 25).
To evaluate feasibility of implementation, including adherence to the program.
Program adherence captured through platform telemetry.
Time frame: From post-intervention (week 13) to follow-up (week 25)
To evaluate feasibility of implementation, including usability.
Usability measured by System Usability Score (SUS) score from 0 to 100 where higher scores mean better outcomes.
Time frame: From post-intervention (week 13) to follow-up (week 25)
To evaluate feasibility of implementation, including satisfaction and retention.
Participant satisfaction and perceived benefit will be assessed through a brief set of items evaluating overall satisfaction with the program, perceived usefulness and perceived improvement in daily functioning.
Time frame: From post-intervention (week 13) to follow-up (week 25).
To explore indicators of acceptability.
Acceptability assessed using the Acceptability of Intervention Measure (AIM) scale which goes from 1 to 5 and higher scores mean better outcomes.
Time frame: From post-intervention (week 13) to follow-up (week 25).
To explore indicators of appropriateness.
Appropriateness assessed using Intervention Appropriateness Measure (IAM) scale which goes from 1 to 5 where higher scores mean better outcomes.
Time frame: From post-intervention (week 13) to follow-up (week 25).
To explore indicators of implementation.
Feasibility assessed using the Feasibility of Intervention Measure (FIM) scale which goes from 1 to 5 and higher scores mean better outcomes.
Time frame: From post-intervention (week 13) to follow-up (week 25).
To explore preliminary economic feasibility indicators.
Economic feasibility will be explored through resource-use variables professional time required for support or monitoring, number and type of user support contacts or technical incidents requiring intervention).
Time frame: From post-intervention (week 13) to follow-up (week 25).
Plan to share: No — The individual participant data (IPD) will not be shared publicly due to the nature of the study, the limited sample size, and the sensitive nature of the data related to cognitive status of the participants.
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Nov 2026, 4 months after the start.
Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 4 months is below that.
Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia